Aldosterone inhibits nitric oxide synthesis in rat vascular smooth muscle cells induced by interleukin-1 beta.

No abstract is available for this paper.

• Publication year

  1995

• Venue

  European Journal of Pharmacology

• Publication date

  1995-07-18

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/0922-4106(95)90018-7PMID 8575535
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Ouabain enhances nitric oxide synthesis in rat vascular smooth muscle cells induced by interleukin-1 beta.

  1995cited by this paper
• Arterial smooth muscle cells express nitric oxide synthase in response to endothelial injury

  1994cited by this paper
• Nitric oxide synthesis in rat cardiac myocytes and fibroblasts.

  1994cited by this paper
• Endothelial nitric oxide and cardiovascular disease

  1994cited by this paper
• Angiotensin II inhibits cytokine-stimulated inducible nitric oxide synthase expression in vascular smooth muscle cells.

  1994cited by this paper
• Cytokine‐induced expression of an inducible type of nitric oxide synthase gene in cultured vascular smooth muscle cells

  1993cited by this paper
• [Production of mineralocorticoid and enzyme expression for steroidogenesis in blood vessels as components of the vascular auto-/paracrine system].

  1993cited by this paper
• 血管におけるauto-/para-crineとしてのステロイド生成とその代謝酵素系

  1993cited by this paper
• Molecular mechanisms of nitric oxide regulation. Potential relevance to cardiovascular disease.

  1993cited by this paper
• Regulation of Na-K-ATPase gene expression by aldosterone in vascular smooth muscle cells.

  1993cited by this paper
• Regulation of Na,K-adenosine triphosphatase gene expression by sodium ions in cultured neonatal rat cardiocytes.

  1993cited by this paper
• L-arginine inhibits balloon catheter-induced intimal hyperplasia.

  1993cited by this paper
• Cyclic AMP-elevating agents induce an inducible type of nitric oxide synthase in cultured vascular smooth muscle cells. Synergism with the induction elicited by inflammatory cytokines.

  1993cited by this paper
• Balloon injury and interleukin-1 beta induce nitric oxide synthase activity in rat carotid arteries.

  1992cited by this paper
• Immunohistochemical and biochemical evidence for a cardiovascular mineralocorticoid receptor.

  1992cited by this paper
• Polyclonal antibody against an inducible form of nitric oxide synthase purified from the liver of rats treated with Propionibacterium acnes and lipopolysaccharide.

  1992cited by this paper
• Interleukin 6 stimulates growth of vascular smooth muscle cells in a PDGF-dependent manner.

  1991cited by this paper
• Nitric oxide: physiology, pathophysiology, and pharmacology.

  1991cited by this paper
• Diet-induced atherosclerosis increases the release of nitrogen oxides from rabbit aorta.

  1990cited by this paper
• Nitric oxide-generating vasodilators and 8-bromo-cyclic guanosine monophosphate inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells.

  1989cited by this paper
• Vascular endothelial cells synthesize nitric oxide from L-arginine

  1988cited by this paper
• Selective Attenuation of Endothelium‐Mediated Vasodilation in Atherosclerotic Human Coronary Arteries

  1988cited by this paper
• Endothelial renin-angiotensin pathway: evidence for intracellular synthesis and secretion of angiotensins.

  1987cited by this paper
• Analysis of nitrate, nitrite, and [15N]nitrate in biological fluids.

  1982cited by this paper
• Steroid hormones and the kidney.

  1981cited by this paper
• Mineralocorticoid binding in cultured smooth muscle cells and fibroblasts from rat aorta.

  1981cited by this paper

• Additive Effects of Esaxerenone, a Nonsteroidal Mineralocorticoid Receptor Blocker, on Cardioplegic Arrest in Rat Hearts

  2024cites this paper
• Effect of esaxerenone on ischemia and reperfusion injury in rat hearts.

  2023cites this paper
• Safety and Efficacy of Spironolactone in Dialysis-Dependent Patients: Meta-Analysis of Randomized Controlled Trials

  2022cites this paper
• Characterization of Circulating Extracellular Vesicle Surface Antigens in Patients With Primary Aldosteronism

  2021cites this paper
• Aldosterone and the mineralocorticoid receptor in renal injury: A potential therapeutic target in feline chronic kidney disease

  2020cites this paper
• The renin‐angiotensin‐aldosterone system and its suppression

  2019cites this paper
• Characterization and Gene Expression Analysis of Serum-Derived Extracellular Vesicles in Primary Aldosteronism.

  2019cites this paper
• Hypertension with primary aldosteronism is associated with increased carotid intima‐media thickness and endothelial dysfunction

  2019cites this paper
• Asymmetric Dimethylarginin (ADMA) as a Marker of Endothelial Dysfunction in Primary Aldosteronism

  2016cites this paper
• Hyperaldostéronisme primaire : nouvelles données morphologiques et fonctionnelles sur le ventricule gauche en échocardiographie bidimensionnelle

  2016cites this paper
• Mineralocorticoid Receptor Antagonist Pretreatment to MINIMISE Reperfusion Injury After ST‐Elevation Myocardial Infarction (The MINIMISE STEMI Trial): Rationale and Study Design

  2015cites this paper
• Increased aortic stiffness elevates pulse and mean pressure and compromises endothelial function in Wistar rats.

  2014cites this paper
• Vad har Spironolakton för effekt på hjärta, kärl och det sympatiska nervsystemet hos hjärtsviktspatienter?

  2014influential citation
• Spironolactone improves endothelial and cardiac autonomic function in non heart failure hemodialysis patients

  2013cites this paper
• Primary Aldosteronism: Progress in Diagnosis, Therapy, and Genetics

  2013cites this paper
• Reduction of Aldosterone Production Improves Renal Oxidative Stress and Fibrosis in Diabetic Rats

  2013cites this paper
• Aldosterone predicts major adverse cardiovascular events in patients with acute myocardial infarction

  2012cites this paper
• Effects of carbenoxolone on flow-mediated vasodilatation in healthy adults.

  2011cites this paper
• Study of the mechanisms of aldosterone prothrombotic effect in rats

  2011cites this paper
• Effects of aldosterone and related steroids on LPS‐induced increased expression of inducible NOS in rat aortic smooth muscle cells

  2011cites this paper
• Failure with Renal Artery Ischemia

  2011cites this paper
• Chapter 17 – Alterations in the Peripheral Circulation in Heart Failure

  2011cites this paper
• The effect of spironolactone on cardiovascular disease in early stage chronic kidney disease

  2011cites this paper
• Management of heart failure with renal artery ischemia.

  2011cites this paper
• Protecting the kidneys in lupus nephritis

  2011cites this paper
• Rationale for an early aldosterone blockade in acute myocardial infarction and design of the ALBATROSS trial.

  2010cites this paper
• [Prothrombotic aldosterone action--a new side of the hormone].

  2010cites this paper
• Renoprotection, renin inhibition, and blood pressure control: the impact of aliskiren on integrated blood pressure control

  2010cites this paper
• Hypertension and dyslipidemia in the pathophysiology of chronic kidney disease

  2009cites this paper
• Aldosterone and cardiovascular disease.

  2009cites this paper
• Exploring the potential synergistic action of spironolactone on nitric oxide-enhancing therapy: insights from the African-American Heart Failure Trial.

  2008cites this paper
• Aldosterone induces endothelial dysfunction in resistance arteries from normotensive and hypertensive rats by increasing thromboxane A2 and prostacyclin

  2008cites this paper
• Inducible Nitric Oxide S ynthase and Atherosclerosis

  2008cites this paper
• Aldosterone receptor blockade in patients with left ventricular systolic dysfunction following acute myocardial infarction.

  2008cites this paper
• Steroids and nitric oxide in sepsis.

  2008cites this paper
• Management of heart failure with renal artery ischemia.

  2008cites this paper
• MILDRONATE EFFECT ON ENDOTHELIUM-DEPENDENT VASODILATION IN PATIENTS WITH CHRONIC HEART FAILURE: DOUBLE BLIND CROSSOVER STUDY

  2008cites this paper
• Comparison of the effect of simvastatin, spironolactone and L-arginine on endothelial function of aorta in hereditary hypertriglyceridemic rats.

  2007cites this paper
• Predominant effect of A-type natriuretic peptide on reduction of oxidative stress during the treatment of patients with heart failure.

  2007cites this paper
• Estrogen and Angiotensin II Interactions Determine Cardio-Renal Damage in Dahl Salt-Sensitive Rats with Heart Failure

  2007cites this paper
• Steroids and nitric oxide in sepsis 1700 1700 release of adrenocorticotropic hormone ( ACTH ) from the anterior pituitary into the blood

  2007cites this paper
• Mecanismo de acción de la eplerenona

  2006cites this paper
• Aldosterone antagonism improves endothelial-dependent vasorelaxation in heart failure via upregulation of endothelial nitric oxide synthase production.

  2006cites this paper
• Aldosterone Blockade Over and Above ACE-Inhibitors in Patients with Coronary Artery Disease but without Heart Failure

  2006cites this paper
• Value of Non-antiarrythmic Drugs in Preventing Sudden Cardiac Death: Aldosterone Antagonists

  2006cites this paper
• Cytochrome P450 enzymes: central players in cardiovascular health and disease.

  2006cites this paper
• Impact of plasma aldosterone levels for prediction of in-stent restenosis.

  2006cites this paper
• High Plasma Aldosterone Levels on Admission Are Associated With Death in Patients Presenting With Acute ST-Elevation Myocardial Infarction

  2006cites this paper
• Cardiovascular effects of aldosterone and post-acute myocardial infarction pathophysiology.

  2006cites this paper
• Cross-Sectional Relations of Multiple Biomarkers From Distinct Biological Pathways to Brachial Artery Endothelial Function

  2006cites this paper
• Aldosterone blockade in post‐acute myocardial infarction heart failure

  2006cites this paper
• Participation of Prostacyclin in Endothelial Dysfunction Induced by Aldosterone in Normotensive and Hypertensive Rats

  2005cites this paper
• Role of SGK1 in nitric oxide inhibition of ENaC in Na+-transporting epithelia.

  2005cites this paper
• Regression of existing glomerulosclerosis by inhibition of aldosterone.

  2005cites this paper
• Adverse cardiorenal effects of aldosterone: is aldosterone antagonism beneficial?

  2005cites this paper
• The Role of Aldosterone Blockers in the Management of Chronic Heart Failure

  2005cites this paper
• Eplerenone Reduces Oxidative Stress and Enhances eNOS in SHR: Vascular Functional and Structural Consequences

  2005cites this paper
• Antihypertensive therapy: role of aldosterone antagonists.

  2005cites this paper
• L'inibizione dell'aldosterone nell'ipertensione arteriosa

  2005cites this paper
• The -344T>C promoter variant of the gene for aldosterone synthase (CYP11B2) is not associated with cardiovascular risk in a prospective study of UK healthy men.

  2004cites this paper
• Heart failure ALDOSTERONE BLOCKADE IN CARDIOVASCULAR DISEASE

  2004cites this paper
• Aldosterone-induced vasculopathy.

  2004cites this paper
• Hämodynamische und immunmodulatorische Effekte von niedrig dosiertem Hydrocortison im septischen Schock

  2004cites this paper
• Aldosterone and cardiovascular remodelling: focus on myocardial failure

  2004cites this paper
• Fiftieth anniversary of aldosterone: from discovery to cardiovascular therapy.

  2004cites this paper
• Aldosterone blockade in cardiovascular disease

  2004cites this paper
• The clinical implications of aldosterone escape in congestive heart failure

  2004cites this paper
• Pleiotropic actions of aldosterone and the effects of eplerenone, a selective mineralocorticoid receptor antagonist.

  2004cites this paper
• Activation of the ligand-mineralocorticoid receptor functional unit by ancient, classical, and novel ligands. Structure-activity relationship.

  2004cites this paper
• Aldosterone in the development and progression of renal injury.

  2004cites this paper
• Aldosterone modulates neural vasomotor response in hypertension: role of calcitonin gene-related peptide.

  2004cites this paper
• Eplerenone: selective aldosterone antagonism in management of cardiovascular and renal disease.

  2004cites this paper
• Effect of spironolactone on endothelial function in patients with congestive heart failure on conventional medical therapy.

  2004cites this paper
• Impaired Endothelium-Dependent Flow-Mediated Vasodilation in Hypertensive Subjects With Hyperaldosteronism

  2004cites this paper
• Aldosterone inhibits inducible nitric oxide synthase in neonatal rat cardiomyocytes.

  2003cites this paper
• Aldosterone plays a pivotal role in the pathogenesis of thrombotic microangiopathy in SHRSP.

  2003cites this paper
• Aldosterone: cardiovascular assault.

  2002cites this paper
• Aldosterone as a Mediator in Cardiovascular Injury

  2002cites this paper
• Aldosterone induces acute endothelial dysfunction in vivo in humans: evidence for an aldosterone-induced vasculopathy.

  2002cites this paper
• Impact of aldosterone on vascular pathophysiology.

  2002cites this paper
• Impaired endothelium-mediated vasodilation in heart failure: clinical evidence and the potential for therapy.

  2002cites this paper
• Eplerenone — A Novel Selective Aldosterone Blocker

  2002cites this paper
• Aldosterone Receptor Blockade in the Management of Heart Failure

  2002cites this paper
• Review: Aldosterone-induced vasculopathy: a new reversible cause of cardiac death

  2001cites this paper
• Aldosterone in renal disease

  2001cites this paper
• Aldosterone as a mediator of progressive renal disease: pathogenetic and clinical implications.

  2001cites this paper
• Mediators of Chronic Heart Failure: How Drugs Work

  2001cites this paper
• Reversal of endothelial dysfunction in humans.

  2001cites this paper
• Aldosterone antagonists in the treatment of hypertension and target organ damage

  2001cites this paper
• Aldosterone in renal disease.

  2001cites this paper
• Aldosterone and vascular damage

  2000cites this paper
• Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure.

  2000cites this paper
• Testosterone inhibits expression of inducible nitric oxide synthase in murine macrophages.

  2000cites this paper
• The role of corticosteriods in the regulation of vascular tone.

  1999cites this paper
• Endocrine Control of Potassium Balance

  1999cites this paper
• [Rigidity of large arteries and cardiovascular risk. epidemiological aspects and genetic determinants].

  1999cites this paper
• [The cardiovascular steroid system].

  1998cites this paper
• Inducible nitric oxide synthase and atherosclerosis

  1998cites this paper
• Regulation of the cerebral circulation: role of endothelium and potassium channels.

  1998cites this paper
• Aldosterone Overproduction and CYP11B2 mRNA Overexpression in Vessels of Spontaneously Hypertensive Rats

  1998cites this paper